HELP Copays Act
Summary
The HELP Copays Act (S.864) would require group health plans to count financial assistance from drug manufacturers and non-profits toward patient deductible and out-of-pocket limits. The bill is in committee with 26 cosponsors and a companion House bill. If enacted, it would benefit pharmaceutical companies by boosting drug utilization, while insurers face higher claims costs. No market data is provided, but structural impacts are clear.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The HELP Copays Act would mandate counting manufacturer copay assistance toward patient deductibles and OOP max, boosting drug utilization.
- 2.Pharmaceutical companies (LLY, MRK, PFE, ABBV, JNJ) are primary beneficiaries with estimated 1-3% revenue uplift.
- 3.Health insurers (UNH) face increased drug claim costs, but the impact is mitigated by PBM capabilities and represents a small percentage of total revenue.
Market Implications
The HELP Copays Act directly impacts healthcare sector dynamics. Pharmaceutical companies with strong branded drug portfolios (LLY, MRK, PFE, ABBV, JNJ) could see modest revenue gains if the bill passes, due to improved effectiveness of copay cards. Insurers like UNH may face higher medical costs but the impact is small relative to their scale. No market price data is available, but the structural bias is positive for pharma and slightly negative for insurers.
Full Analysis
The HELP Copays Act (S.864) was introduced on March 5, 2025 by Sen. Roger Marshall (R-KS) and has 26 cosponsors including both parties. Hearings were held in the Senate HELP Committee on March 19, 2026. The bill amends the Public Health Service Act to require that amounts paid by or on behalf of individuals—including financial assistance from non-profit organizations and prescription drug manufacturers—count toward the deductible, coinsurance, copayment, and out-of-pocket limit. A companion bill (HR6423) has been introduced in the House. The bill is still in committee and has not passed either chamber.
The legislation involves no direct government funding; it is a regulatory mandate on private health insurance plans. The money trail runs through insurance claims: by counting manufacturer copay assistance toward out-of-pocket limits, patients will hit their deductibles and maximums faster, increasing insurer liability for drug costs. Pharmaceutical companies benefit because patients are more likely to fill prescriptions when copay assistance is effective, boosting sales volume.
No convergence signals are present in the provided data. The bill stands alone as a targeted health policy initiative.
Structural winners are pharmaceutical companies with high-priced branded drugs that use copay assistance programs: $LLY (revenue $34.1B), $MRK ($60.1B), $PFE ($59.6B), $ABBV ($54.3B), ($85.2B). For these, the bill enhances their existing patient assistance programs, potentially increasing net revenue by 1-3% depending on drug mix. Structural losers are health insurers: (revenue $371.6B) faces higher drug claim costs, though its Optum PBM may offset some impact through formulary adjustments. The net effect on UNH is bearish but moderate given its diversified business.
Timeline: The bill has advanced from introduction to hearings, indicating active committee work. However, it has not yet passed the Senate. The next steps are committee markup and then a floor vote. The companion House bill adds momentum but passage this Congress is uncertain. Legislative velocity is moderate.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Requires health plans to count manufacturer copay assistance toward patient deductible and out-of-pocket maximum.
Who must act
Group health plans and health insurance issuers covered under PHS Act.
What happens
Reduces effective patient cost-sharing for branded drugs, increasing prescription fill rates and adherence.
Stock impact
LLY's key drugs (Mounjaro, Zepbound) have high list prices and rely on copay cards; this bill enhances their effectiveness, likely boosting net revenue by 1-3%.
What the bill does
Requires health plans to count manufacturer copay assistance toward patient deductible and out-of-pocket maximum.
Who must act
Group health plans and health insurance issuers covered under PHS Act.
What happens
Reduces effective patient cost-sharing for branded drugs, increasing prescription fill rates and adherence.
Stock impact
MRK's branded drugs (Keytruda, Gardasil) benefit from improved copay assistance pass-through; revenue impact estimated at 1-2% of pharma revenue.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
Wildlife Health Coordination and Zoonotic Disease Prevention Act of 2026
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
A bill to provide for digital communication of prescribing information for drugs (including biological products), and for other purposes.
A bill to require regulatory review of pharmaceutical products from Chinese entities, and for other purposes.
Biosimilar Red Tape Elimination Act
To amend the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to require health insurance coverage of drugs indicated for the treatment of autoimmune diseases and certain blood disorders.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →